FBLN5

(redirected from UP50)

FBLN5

A gene on chromosome 14q32.1 that encodes a secreted, extracellular matrix protein containing an Arg-Gly-Asp (RGD) motif and calcium-binding EGF-like domains, which promotes adhesion of endothelial cells by interaction of integrins and the RGD motif. The FBLN5 protein produced is expressed in intimal vascular smooth muscle cells and endothelial cells during vascular development, and in remodeling during atherosclerosis and after balloon-catheter-induced injury.

Molecular pathology
FBLN5 mutations cause cutis laxa type I and age-related macular degeneration type 3.
Mentioned in ?
References in periodicals archive ?
A Komatsu PC300 equipped with a Labounty UP50 concrete pulverizer sized up the material once it was on the ground.
The third protocol, UP50, involved 16 healthy subjects (eight female) exposed to approximately 50 [micro]g/[m.
For UP50 and UPASTHMA, measurements were also obtained 45 hr after exposure.
The adhesion markers shown in Table 2 were measured in each of the study protocols, except for CD18, which was measured in UP50 and UPASTHMA only.
UPREST, UPASTHMA, and UP50 used a standard, two-period crossover design in which each subject received both particles and air.
In each of the protocols involving exercise (UPDOSE, UP50, and UPASTHMA), consistent postexposure increases were seen in the total leukocyte count and the percentage of PMNs, with decreases in the percentage of eosinophils and monocytes.
2004b) that, in the UP50 protocol, UFP exposure caused reductions in the diffusing capacity for carbon monoxide, without effects on the forced vital capacity, consistent with reduced vascular perfusion or reduced ventilation/perfusion matching.
Females also showed decreased eosinophils in the UP50 protocol (Figure 5C).